Key statistics
On Monday, Actinogen Medical Ltd (3AC:FRA) closed at 0.0235, 193.75% above the 52 week low of 0.008 set on Jun 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.0235 |
|---|---|
| High | 0.0235 |
| Low | 0.0235 |
| Bid | -- |
| Offer | -- |
| Previous close | 0.023 |
| Average volume | 1.87k |
|---|---|
| Shares outstanding | 3.19bn |
| Free float | 2.64bn |
| P/E (TTM) | -- |
| Market cap | 137.25m AUD |
| EPS (TTM) | -0.005 AUD |
Data delayed at least 15 minutes, as of Feb 09 2026 07:12 GMT.
More ▼
Announcements
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
- Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
- Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
